Neuroprotective Effect of Mas Activation by BIO101 in Vincristine‐Induced Small Fiber Neuropathy
Journal of the Peripheral Nervous System · 2025
DOI: 10.1111/jns.70055 ↗At a glance
Journal article in Journal of the Peripheral Nervous System, 2025. Written by Simon Frachet and 8 co-authors. Institution: NeurIT Neuropathies et Innovations Thérapeutiques UR 20218, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France. Major MEDLINE topics: Vincristine, Neuroprotective Agents, Antineoplastic Agents, Phytogenic, Small Fiber Neuropathy. 42 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background and Aims Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant side effect that limits the dosage of many anticancer therapies, such as vincristine. At present, there are no effective pharmacological treatments to prevent CIPN. The Mas receptor (MasR) is expressed in the peripheral nervous system and plays a role in pain modulation. While the antinociceptive properties of MasR activation in CIPN have been documented, its potential neuroprotective effects have not been explored in the peripheral nervous system. BIO101, a highly purified form of the MasR activator 20‐hydroxyecdysone, exhibits a positive safety profile in a Phase 1 study without any serious adverse events.
Methods
This study aimed to investigate the neuroprotective effects of BIO101 in a mouse model of vincristine‐induced peripheral neuropathy (VIPN). Swiss mice were treated with daily doses of vincristine. VIPN was evaluated through repeated measurements of tactile sensitivity, quantification of intraepidermal nerve fibers (IENF) and dorsal root ganglion (DRG) neurons, and ultrastructural analysis of the sciatic nerve.
Results
Vincristine led to mechanical allodynia and reduced the density of IENF, DRG neurons, and unmyelinated nerve fibers in the sciatic nerve. Prophylactic administration of BIO101 mitigated vincristine‐induced symptoms and nerve damage. The neuroprotective effect of BIO101 was nullified when the MasR antagonist A779 was administered; confirming the involvement of MasR.
Interpretation
Therefore, BIO101 emerges as a safe and promising preventive treatment against vincristine‐induced small fiber neuropathy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- NeurIT Neuropathies et Innovations Thérapeutiques UR 20218, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France.
- Department of Neurology, Reference Center for Rare Peripheral Neuropathies, University Hospital of Limoges, Limoges, France.
- Biophytis, Sorbonne Université - BC9, Paris, France.
- UMR INSERM 1083 CNRS 6015 MITOVASC Laboratory, CarMe Team, University of Angers, Angers, France.
- Transversal and Territorial Therapeutic Education Unit (UTTEP87), University Hospital of Limoges, Limoges, France.
ORCID profiles: Simon Frachet, Aurore Danigo
Cite
APA
Frachet, S., Danigo, A., Latil, M., Dilda, P. J., Bessaguet, F., Richard, L., Sturtz, F., Magy, L., & Demiot, C. (2025). Neuroprotective Effect of Mas Activation by BIO101 in Vincristine‐Induced Small Fiber Neuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70055
Vancouver
Frachet S, Danigo A, Latil M, Dilda PJ, Bessaguet F, Richard L, et al. Neuroprotective Effect of Mas Activation by BIO101 in Vincristine‐Induced Small Fiber Neuropathy. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.70055
BibTeX
@article{Frachet2025,
author = {Frachet, Simon and Danigo, Aurore and Latil, Mathilde and Dilda, Pierre J and Bessaguet, Flavien and Richard, Laurence and Sturtz, Franck and Magy, Laurent and Demiot, Claire},
title = {Neuroprotective Effect of Mas Activation by BIO101 in Vincristine‐Induced Small Fiber Neuropathy},
journal = {Journal of the Peripheral Nervous System},
year = {2025},
doi = {10.1111/jns.70055}
}
EUVIMED